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Introduction
Although  there  has  been  continuing  discussion  and 
debate over the ethical implications and clinical utility of 
a large-scale genotyping for an individual patient [1-3], 
the  issue  is  somewhat  moot.  Patients  are  now  being 
genotyped using either (i) measurement platforms run by 
several  different  direct-to-consumer  companies  that 
sequence  nearly  a  million  single  nucleotide  polymor-
phisms  (SNPs)  [4],  or  (ii)  whole  genome  sequencing, 
which is beginning to be offered to selected individuals 
[5-8]. Patients are beginning to present to their healthcare 
provider  before  or  during  an  evaluation,  including  an 
extensive genotyping scan [9]. It may appear over  whelm-
ing and a nearly impossible task to take the complexity of 
genetic variation and interpret it in the context of the 
enormous amount of literature on human genetics [10], 
some  of  which  seems  mercurial  and  contradictory. 
However  daunting,  it  is  incumbent  upon  a  healthcare 
provider to try to help patients make informed decisions 
in light of the information available, and to not ignore 
this genetic information.
Discussion
Although  DNA  variants  unique  to  an  individual,  or  at 
least extremely rare in the general population, may have 
major impact on personal phenotypes and may explain 
much  of  the  ‘missing  heritability’  [11,12]  of  common 
variants, we currently have very little power to interpret 
the  impact  or  predictive  power  of  these  rare  variants. 
Additionally, individual sequence data, which are able to 
probe for more rare variants, are not yet as common as 
parallel  genotyping  assays,  which  primarily  probe 
common  variants.  There  is  a  large  body  of  published 
research associating common variants with disease [13]. 
Admittedly, those relationships are through association, 
which does not necessarily indicate a direct functional 
relationship for the outcome or phenotype being studied. 
However, having a direct model of mechanism has never 
been a requirement for the value of a medical test. Many 
features used in physical examinations or laboratory tests 
have an indirect relationship with the clinical phenotype 
(typically disease state) being measured. For instance, the 
well-known relationship between clubbing and impaired 
lung function is through association, not mechanism, but 
that does not reduce the predictive value. Association of 
a genotype with clinical phenotype has value as a predic-
tive tool independent of mechanism.
We envision that patients may present to a healthcare 
provider  with  a  large  panel  of  genotyping  studies  or  a 
whole genome sequence (both of these are referred to 
here as DNA analysis) generally for three reasons. The 
first might be to seek reproductive counseling, and there 
is  already  extensive  existing  methodology  in  this  area, 
including professional certification for counselors in the 
USA  and  Canada  by  the  American  Board  of  Genetic 
Counseling. The second might be for an individual with 
clinical  complaints,  and  the  genotyping  analysis  might 
have been performed with the hope of providing assis-
tance in the refinement of a diagnosis or an improved, 
personalized  treatment  plan.  The  third  might  be  for  a 
healthy  patient  looking  for  suggestions  into  lifestyle 
modifi  cations  or  information  on  long-term  prognosis 
and  early  identification  of  potential  problems;  this 
situation is not unique to a genetic screen and is typically 
the  goal  with  a  well  physical.  Here,  we  are  addressing 
patients presenting for the latter two reasons.
By  viewing  a  DNA  analysis  as  a  series  of  multiple 
laboratory  tests  that  each  have  predictive  power  for 
different phenotypes, it becomes clear how these fit into 
the well-established methods of evidence based medicine 
[14-16].  The  measurement  of  each  DNA  variant  turns 
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ratio for phenotype (we will focus primarily on current or 
future disease state as the phenotype of interest) based 
on the result of that test.
Armed with a reasonable assessment of pre-test odds, 
the  framework  of  evidence  based  medicine,  which  has 
been  taught  in  medical  schools  and  in  residency  pro-
grams for decades, simply multiplies the likelihood ratios 
of disease state, given the results of the tests, to produce a 
post-test  odds  of  disease.  The  fact  that  the  results  of 
genotype analysis of any individual variant are extremely 
precise  should  not  be  confused  with  the  fact  that 
individual  tests  for  disease  need  not  be  exceptionally 
accurate to have value. The DNA analysis is just a very 
large panel of such tests.
Calculation of likelihood ratios, and pre- and post-test 
probabilities
A  likelihood  ratio  is  the  ratio  of  the  probability  of  a 
positive  test,  in  this  case  a  particular  genotype,  in  a 
diseased person to that in a non-diseased person:
Likelihood ratio = Probability of genotype in diseased person/
Probability of genotype in non-diseased person = LRi
Likelihood  ratios  multiplied  by  the  pre-test  odds  of 
disease give the post-test odds of disease (Table 1), and 
these likelihood ratios may be chained together (Figure 1):
Pre-test odds = Probability of disease/1 - Probability of 
disease
Pre-test odds × LR1 × LR2 ×…× LRn = Post-test odds
Post-test probability = Post-test odds/Post-test odds + 1
The  assumption  of  independence  made  here  is  that 
each  test  is  independent  of  one  another.  Note  that 
assuming  independence  of  tests  is  actually  a  different 
assumption than assuming that each variant contributes 
independently  to  risk.  The  independence  of  risk 
contributions may be an accurate model if each genetic 
variant measured does causally contribute independently 
to risk, but there is only very little indication [17] that 
this is broadly the case for most genetic associations, and 
there are difficulties with many models that do assume 
independent  risk  contributions  [18].  If  we  view  each 
measured variant as an independent test probing disease 
state, this is arguably closer to our understanding of their 
use as markers associated with disease instead of actual 
causal variants. In this case, assuming independence as 
tests of disease is a more appropriate approximation.
A key advantage of considering genotyping assays by 
likelihood ratios is that this methodology directly takes 
the  prior  probabilities  into  account.  Genetic  features 
suggesting relatively dramatic increase in associated risk 
may still only suggest modest post-test probabilities of 
rare diseases. Variants that do not contribute dramatically 
to  risk  will  leave  common  diseases  as  being  common 
(that is, having a high post-test probability) and should 
not  substantially  change  most  current  guidelines  for 
preventative screening. In addition, the specific pre-test 
probabilities are also adjustable in the context of a patient 
with other clinical findings. The calculation of post-test 
probabilities  in  this  manner  will  allow  the  results  of 
genetic screens to more easily fit into discussions of the 
numbers needed to treat, numbers needed to harm, and 
many issues in cost-benefit analysis.
Considering genotyping assays by likelihood ratios and 
post-test  probabilities  [16]  also  addresses  previously 
suggested  ‘incidentalome’  issues  [19],  where  incidental 
findings,  even  many  of  them,  that  weakly  suggest 
increased  likelihood  of  rare  diseases  will  be  largely 
irrelevant in a patient free from clinical complaints and 
with correspondingly low post-test probabilities of these 
diseases.  Physicians  have  been  taught  to  consider 
threshold post-test probabilities for continuing testing or 
initiating therapy, with thresholds set based on careful 
consideration  of  the  risks  and  benefits  of  continued 
testing or initiation of therapy. If physicians are presented 
with  panels  of  post-test  probabilities,  instead  of  being 
presented with genotypes or odds ratios, we suggest they 
Table 1. Example calculations of post-test probabilities 
Type of disease and associated variants  Pre-test probability of disease (%)  Likelihood ratio  Post-test 
probability of disease (%)
Common disease, weakly associated variant  15.0  1.1  16.256
Common disease, several weakly associated variants  15.0  1.1 × 1.1 × 1.1 × 1.1 = 1.46  20.486
Rare disease, weakly associated variant  0.01  1.1  0.011
Rare disease, strongly associated variant  0.01  5  0.050
Rare disease, several weakly associated variants  0.01  1.1 × 1.1 × 1.1 × 1.1 = 1.46  0.015
Rare disease, several moderately associated variants  0.01  2 × 2 × 2 × 2 = 16  0.160
Post-test probabilities may be calculated for common or rare diseases with weakly and strongly associated variants using example values for likelihood ratios and pre-
test probabilities. The definition of strongly versus weakly associated is in the context of genetic associations, where likelihood ratios from large-scale studies rarely 
reach higher than 3. Many clinical laboratory tests have likelihood ratios of 10 or more.
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courses based on post-test probabilities.
Challenges
Unfortunately,  much  of  the  information  necessary  to 
support  this  method  of  using  likelihood  ratios  is  not 
being published in the primary publications associating 
genotypes  with  disease.  Although  many  studies  have 
been  performed  examining  the  association  between 
common variants and disease, many of these reports still 
do not provide enough information to calculate a likeli-
hood ratio from a specific genotype, do not characterize 
the sample population and the prior probability of disease 
in  this  population,  or  do  not  make  clear  what  other 
variants were measured to help adjust for multiple hypo-
thesis testing and other biases.
Traditionally, the published literature on genetic asso-
ciations  has  focused  on  suggesting  interesting  variants 
with possible mechanistic involvement in the disease of 
study. Hence, authors may only report an odds ratio as a 
measure of effect size, and a P value to show that the 
variant is significantly associated with the disease. Many 
such studies do not even report the risk genotype at the 
site of the SNP; this is a particular problem because the 
relationship  of  the  common  allele  in  the  population 
under study to a reference genome is unknown, and the 
reference  genome  may  actually  contain  the  risk-
associated allele. For example, a study that reports that 
having a variation at an identified location in the genome 
doubles the risk for a disease, without reporting which 
variant  (A,  C,  T  or  G)  is  actually  associated  with  the 
increase of risk, is failing to report essential information.
We recently curated 2,174 articles reporting primary 
data  on  gene-disease  associations  of  variants  in  the 
National Center for Biotechnology Information (NCBI) 
SNP database (dbSNP) [20]. Of these publications, only 
46%  contained  information  on  actual  genotype-asso-
ciated risk, enabling the calculation of a likelihood ratio 
yielding  a  total  of  2,092  disease-variant  associations. 
Although  any  particular  genetic  association  study  may 
not be intended for use in informing a clinical diagnostic 
test  or  interpretation,  information  on  the  actual  pro-
portion/frequency of subjects with each associated geno-
typic variant in the relevant phenotype categories (such 
as with and without disease) should be made available for 
use in further studies and meta-analyses. This informa-
tion  aids  in  attempts  at  replication  of  results  and  in 
calculating overall estimates of the power of a particular 
genotype  to  predict  disease  state.  The  prostate  cancer 
study by Duggan and colleagues [21] contains a particu-
larly  illuminating  example  of  this  kind  of  detailed 
reporting in Table 2 of the article. At a bare minimum, 
the actual risk allele should be reported; this is something 
not explicitly required by current guidelines [22].
One  reason  that  additional  data  specifying  the  exact 
proportion  of  individuals  of  each  genotype  in  each 
disease category is not given in publications is possibly 
due to the concern in being able to identify a patient’s 
disease  class  if  detailed  data  from  the  study  are  made 
available [3]. However, such re-identification of disease 
state does still require that one has the patient’s genotype. 
Figure 1. Nomogram for likelihood ratios. The pre-test and 
post-test probabilities and likelihood ratios of any diagnostic test, 
including a genetic test, can be visualized using a nomogram familiar 
to most physicians and medical students. The nomogram shown 
is derived from the Fagan nomogram [14], and modified from one 
generated using a web-based tool [28]. The left side of the figure 
indicates a hypothetical pre-test probability of disease of 27%. Three 
lines represent the three possible genotypes, from top to bottom: 
homozygous risk alleles with a likelihood ratio of 1.61, heterozygous 
alleles with a likelihood ratio of 1.26, and homozygous protective 
alleles with a likelihood ratio of 0.83. The right side of the figure 
indicates three possible post-test probabilities resulting from the 
three genotypes. Multiple such tests can be ‘chained’ together serially, 
if they describe independent risks and cover the same pre-test 
assumptions.
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associated  loci  by  itself  enables  you  to  know  a  con-
siderable amount about that individual, independent of 
their  involvement  in  any  association  studies.  As 
knowledge of human genetics increases, possession of an 
individual’s genetic sequence will continue to be the level 
at which invasion of individual rights and privacy must 
be  protected.  Thus,  the  potential  re-identification  of  a 
patient into a study group should not dissuade researchers 
from  reporting  detailed  information  in  genome-wide 
association studies.
Many  genetic  association  studies  still  do  not  report 
information about the characteristics of the population 
studied,  such  as  age,  gender  and  ethnicity.  This  infor-
mation would substantially increase the clinical relevance 
of the study, and it is a key part of using literature in 
evidence  based  medicine  [23].  Analyses  showing  asso-
ciation of a single biomarker with disease typically report 
very detailed characteristics of the populations studied; 
this is radically different from typical genetic association 
studies,  which  often  report  almost  nothing  about  the 
subjects.
Another  challenge  in  applying  likelihood  ratios  from 
genetic tests is that there are very few sources available 
that provide enough information to calculate the pre-test 
probabilities  of  disease  states,  particularly  in  the  same 
populations under genetic study or populations resemb-
ling  many  presenting  patients.  A  concerted  effort  to 
calculate prevalence and incidence statistics, and report 
them both in genetic association studies and as general 
epidemiological features, will improve the quality of the 
clinical interpretation of genotyping dramatically.
Finally,  there  are  many  established  techniques  for 
addres  sing many of the biases in reporting results of many 
statistical tests, and the ‘winner’s curse’ is a well-known 
phenomenon  [24,25].  Genetic  studies  that  com  bine  a 
discovery for a significant association with disease with an 
estimate  of  associated  risk  are  strongly  biased  to  over-
estimate the level of risk [26]. However, if it is clear which 
associations are measured and what the overall results are, 
we  can  attempt  to  address  these  biases  and  apply  the 
appropriate correction to the estimated effect size, in this 
case predicted risk with a confidence estimate [27].
Conclusions
In  summary,  we  suggest  that  the  methods  for  using  a 
personal genotype to improve clinical evaluation already 
exist. For many diseases, actual genotypes and their asso-
ciated risks are currently being collected in high volumes, 
and as more of these data are presented in publications, 
our ability to assess a patient through genotype will be 
greatly enhanced. If we have reasonable estimates of the 
pre-test  probability  of  disease  for  a  patient,  by  using 
careful methods of meta-analysis to combine the results 
of  studies  that  report  genotype  level  risk  to  compute 
good estimates of likelihood ratios, we can provide post-
test probabilities that a physician can use in assessment 
and  a  patient  could  use  for  potential  lifestyle 
modification.
Abbreviation
SNP, single nucleotide polymorphism.
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